{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"31","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Number of days from stem cell infusion (day +0) to day of neutrophil engraftment (first of three consecutive days with absolute neutrophil count \\> 500)","dispersionType":"Full Range","groups":[{"description":"90Y Zevalin: Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi.","id":"OG000","title":"Zevalin"}],"paramType":"MEDIAN","populationDescription":"Analyzed on intent-to-treat basis","reportingStatus":"POSTED","timeFrame":"Transplant through day 42","title":"Time to Engraftment in Patients Who Proceed to Myeloablative Chemotherapy After Receiving 90Y Zevalin® (Ibritumomab Tiuxetan).","type":"SECONDARY","unitOfMeasure":"Days"}